

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

185,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.  
For more information visit [www.intechopen.com](http://www.intechopen.com)



## Quantitative Determination of Drugs in Dosage Forms as a Tool of Quality Control Studies

Sigrid Mennickent, Marta de Diego,  
Mario Vega and Carmen Gloria Godoy  
*Faculty of Pharmacy,  
University of Concepción, Concepción  
Chile*

### 1. Introduction

Pharmaceutical stability may be defined as the capability of a particular formulation, in a specific container/closure system, to remain within its physical, chemical, microbiological, therapeutic, and toxicological specifications, during transport, storage and use. Chemical degradation may results in a loss of potency or an increase in drugs toxicity, so that clinical use of a medicine must be unacceptable if the degradation is relatively great. When a drug dosage form is altered (by dissolution, pulverization, or addition to other materials) or the environment of the drug is modified by changes in storage conditions, the stability of a drug may be affected [1-5]. Although there are exceptions, 90% of labeled potency generally is recognized as the minimum acceptable potency level (Gennaro, 2000).

Stability testing forms an important part of the process of drug development; it provides evidence on how the quality of drug substance or drug product varies with time under the influence of a variety of environmental factors, such as humidity, temperature, and light. The stability studies of drugs can be performed at the original product ("real-time" tests or long-term tests at specific temperatures and relative humidity representing storage conditions experienced in the distribution chain of the climatic zone(s) of the country or region of the world concerned; accelerated stability tests; pharmacies storage tests) or at remainder doses of these products. The chemical stability is evaluated by testing quantity of drug at different time during the storage (Lund, 1994; USP, 2007).

The aim of the stability studies is to determine the shelf life of the product and its optimum storage conditions (Connors et al., 1986; Lund, 1994; The Sixth ICH International Conference on Armonization of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH], 2003; The United States Pharmacopeia [USP], 2007; Watson, 2005; Yoshioka, 2000).

Therefore, the authors have been developing and validating HPTLC methods with the aim of quantification of drugs in dosage forms, suitable for stability and quality control studies, as at original products as at its remainder doses.

## 2. Drugs

Some drugs analyzed by HPTLC developed methods had been Fluphenazine, Haloperidol and L-DOPA.

### 2.1 Fluphenazine

Fluphenazine is a phenothiazine antipsychotic agent. The drug is a propylpiperazine derivative of phenothiazine (Delgado et al., 1998; Hardman & Limbird, 2006; Mc Evoy, 2006; Sweetman, 2003).




Fig. 1. Chemical structure of Fluphenazine




Fig. 2. Chemical structure of Haloperidol

Drug therapy with fluphenazine is integral for the management of acute psychotic episodes with violent behavior in patients with schizophrenia and generally is required for long-term stabilization to improve symptoms between episodes and to minimize the risk of recurrent acute episodes (Hardman & Limbird, 2006; Mc Evoy, 2006; Sweetman, 2003).

Fluphenazine hydrochloride, decanoate, and enantate are all sensitive to light. Therefore, it is very important to determine the quantity of fluphenazine in its dosage forms because in the presence of light, photolysis occur rapidly, resulting in drug loss and potency reduction (Delgado et al., 1998; Hardman & Limbird, 2006; Mc Evoy, 2006; Moffat et al., 2004; Sweetman, 2003).

## 2.2 Haloperidol

Haloperidol, a butyrophenone derivative, is used for the symptomatic management of psychotic disorders, in the same way that fluphenazine (Delgado et al., 1998; Hardman & Limbird, 2006; Mc Evoy, 2006; Sweetman, 2003).

When haloperidol injection is used, dose is depending on the severity of the illness, the age of the patient and on their response to the pharmacotherapy. Therefore, sometimes the dose corresponded only to a portion of the injection. The portion which is not used is stored for the next administration or is discarded (Delgado et al., 1998; Hardman & Limbird, 2006; Mc Evoy, 2006). The stability of this portion is unknown.

## 2.3 L-DOPA

L-DOPA, the levorotatory isomer of dihydroxyphenylalanine, a natural amino acid, is the precursor of the neurotransmitter dopamine.




Fig. 3. Chemical structure of L-DOPA

The actions of L-DOPA are mainly those of dopamine. Unlike dopamine, L-DOPA can readily enter the Central Nervous System and is used in the treatment of conditions, such as Parkinson's disease, which are associated with depletion of dopamine in the brain (Delgado et al., 1998; Hardman & Limbird, 2006; Mc Evoy, 2006; Sweetman, 2003). L-DOPA is considered by many clinicians the drug of choice in the management of idiopathic parkinsonian syndrome (Mc Evoy, 2006).

It is very important to determine the quantity of L-DOPA in its dosage forms, because, in the presence of moisture or atmospheric oxygen, it is rapidly oxidized resulting in drug loss and potency reduction (Carstensen, 1990; Mc Evoy, 2006; USP, 2007; Sweetman, 2003).

## 3. Methods

Some methods have been reported for the analysis of fluphenazine, haloperidol and L-DOPA in pharmaceutical preparations or in biological fluids. These methods include: spectrophotometry (Blanco et al., 2000; Damiani et al., 2005; Karpinska et al., 2005; Madrakian et al., 2004; Madrakian et al., 2006; Marcolino-Junior et al., 2001; Nagaraja et al., 2001; Nagaralli et al., 2002; Nour El-Dien et al., 2005; Pistonesi et al., 2004; Talebpour et al., 2005), gas chromatography (Jemal et al., 2005), liquid chromatography (Ali & Aboul-Enein, 2005; Chaná et al., 2004; Crevoisier et al., 2003; Fernández et al., 2001; Karimi et al., 2006; Kircherr & Kühn-Velten, 2006; Lea et al., 1982; Nyholm et al., 2002; Sagar & Smyth, 2000;

Saxer et al., 2004; Trabelsi et al., 2002; Wang & Fang, 2006), electrophoresis (Zhang et al., 2001) and voltammetry (Maia et al., 2005). Nevertheless, these methods have often suffered from diverse disadvantages with regard to cost or selectivity, with complex sample preparation procedures, and long analysis time.

Also, one method by TLC was found for determination of fluphenazine hydrochloride in coated tablets, but not in ampoules (Maslanka & Krzek, 2005). Only one paper of stability of haloperidol in injections is discussed in literature, but this paper deals with the stability of haloperidol in 5% dextrose injection (Das Gupta & Stewart, 1982).

### 3.1 High performance thin layer chromatography (HPTLC)

High performance of HPTLC is due to its fastness, solvent economy and high throughput of samples. Chromatography of samples simultaneously with standards is another advantage, allowing to run up to 60 spots simultaneously (27 samples plus standards by each side of the plate). Sensitivity of HPTLC is normally in the range of nanograms in absorbance and picograms in fluorescence mode.

The authors have performed some works using HPTLC for quantitative determination of drugs in biological fluids (Mennickent et al., 2003, 2007a, 2007b, 2009, 2010a, 2010b) and in dosage forms (de Diego et al., 2007a, 2007b, 2010a, 2010b; Mennickent et al., 2007a, 2007b, 2007c, 2010), with exact and reliable results.

The HPTLC methods developed are simple, rapid, with low LOD and LOQ values, with very good accuracy and precision, with robustness, and economical.

#### 3.1.1 Method for fluphenazine injections

For the quantification of fluphenazine in injections, the method was linear in the range of 100 ng/band to 500 ng/band ( $r=0.998$ ). The limit of detection (LOD) and limit of quantification (LOQ) were 1.45 ng/band and 4.40 ng/band, respectively. The intra-assay and inter-assay precision, expressed as the relative standard deviation (RSD), were in the range of 0.73%-1.77% ( $n=3$ ) and 1.18%-1.86% ( $n=9$ ), respectively. The recovery of fluphenazine hydrochloride was in the range 98.29% and 101.53%, with a RSD not higher than 1.87%. The method was selective for fluphenazine hydrochloride from the preservatives of the injections ( $R_f$  for fluphenazine hydrochloride was 0.33, whereas parabens run to the solvent front) (Fig. 4 and Fig. 5).

Stability-indicating capability of the HPTLC assay was studied by forced decomposition of 5 mL of a solution of fluphenazine 1 mg/mL, with 10 mL of 0.1 N hydrochloric acid, 10 mL of 0.1 N sodium hydroxide and 10 mL of 3%  $H_2O_2$ . The mixtures with NaOH and with HCl were heated on hot plates at 60°C for 60 minutes. The mixture with  $H_2O_2$  was stored at room temperature (25°C) for 60 minutes. Then, each mixture was diluted to 100 ng/ $\mu$ L with ethanol and analyzed.

Also, stability-indicating capability of the assay was proved by conducting forced degradation conditions of UV and VIS radiation on fluphenazine standard, as solution of 100 ng/ $\mu$ L.

One degradation product was found after treatment of fluphenazine with HCl, and two degradation products were found after treatment with NaOH.  $R_f$  for fluphenazine was 0.30, whereas  $R_f$  for degradation product with HCl was 0.01, and  $R_f$  for degradation products with NaOH were 0.03 and 0.23 respectively. No degradation product was found with  $H_2O_2$  (Fig. 6).




Fig. 4. Selectivity of the method. Study with parabens. Peak observed: fluphenazine. Rf: retarding factor. AU: absorbance unit




Fig. 5. Picture (video store, CAMAG) of plate at selectivity with parabens. Tracks 1-3 (from left to right of the plate) : fluphenazine hydrochloride; tracks 4-6: fluphenazine hydrochloride + methylparaben; tracks 7-9: fluphenazine hydrochloride + propylparaben; tracks 10-12: fluphenazine hydrochloride + methylparaben + propylparaben. Bands of parabens can be observed at the solvent front




Fig. 6. Degradation study of fluphenazine with HCl, with NaOH and with H<sub>2</sub>O<sub>2</sub>. Tracks 1-3 (from bottom side to the upper side): fluphenazine; tracks 4-6: fluphenazine + HCl; tracks 7-9: fluphenazine + NaOH; track 10-12: fluphenazine + H<sub>2</sub>O<sub>2</sub>. Rf peak fluphenazine = 0.30. Other peaks at tracks 4-9: degradation products. Rf: retarding factor. AU: absorbance unit




Fig. 7. Degradation study of fluphenazine with VIS radiation. Peak 1 (from left to right): fluphenazine; peak 2: degradation product. Rf: retarding factor: AU: absorbance unit



When the drug was exposed to forced degradation with VIS radiation, another peak different to the peak of fluphenazine was found, therefore it could be a degradation product. R<sub>f</sub> for fluphenazine = 0.30 and R<sub>f</sub> for degradation product = 0.56 (Fig. 7). One of the products of photolysis mentioned in literature is a sulphoxide (Lund, 1994). Values for precision study of the method can be observed at the Table 1.

Concentration (ng/uL)	Relative standard deviation (RSD), %	
	Intraassay precision <sup>a</sup>	Intermediate precision <sup>b</sup>
100	1.77	1.86
300	1.64	1.47
500	0.73	1.18

<sup>a</sup> n= 3; analyzed on the same day (for each concentration)  
<sup>b</sup> n= 9; analyzed on three different days (for each concentration)

Table 1. Precision of the HPTLC method for fluphenazine injections

Values founded for the accuracy of the method are presented at the Table 2.

Added concentration (ng/uL)	Found concentration (ng/uL) <sup>a</sup>	Accuracy, % <sup>b</sup>	RSD, % <sup>c</sup>
Intraassay (n=9)			
80	79.90 ± 1.31	99.87	1.64
100	100.45 ± 1.10	100.45	1.10
120	121.84 ± 2.28	101.53	1.87
Interassay (n=27)			
80	78.63 ± 1.34	98.29	1.71
100	99.74 ± 1.65	99.74	1.65
120	120.90 ± 1.83	100.75	1.52

<sup>a</sup> Each value is the mean ± standard deviation.  
<sup>b</sup> (Founded concentration/ added concentration) × 100.  
<sup>c</sup> Relative standard deviation (coefficient of variation).

Table 2. Method accuracy

3.1.2 Method for haloperidol injections

For the quantification of haloperidol in injections, the method was linear between 10ng/band to 100 ng/band (r = 0.999), the method was selective between haloperidol and the parabens, the preservatives in haloperidol lactate injection (R<sub>f</sub> for haloperidol was 0.70, whereas parabens run to the solvent front) (Fig. 8-10). RSD for precision was ≤ 1.92%, and accuracy was from 98.59% to 101.90% of recovery. LOD was 0.89 ng/band and LOQ was 2.71 ng/band. Stability-indicating capability of the HPTLC assay was established by forced decomposition of 5 mL of a solution of haloperidol lactate 1 mg/mL, with 10 mL of 0.1 N hydrochloric acid and 10 mL of 0.1 N sodium hydroxide. The mixture was heated on a hot plate at 60°C for 60 minutes, cooled to room temperature, diluted to 100 ng/uL with methanol and analyzed. Also, stability-indicating capability of the assay was proved by conducting forced degradation conditions of VIS radiation on haloperidol standard.






Fig. 8. Peak of haloperidol. Rf: retarding factor: AU: absorbance unit. Solution concentration: 80 ng/uL




Fig. 9. Selectivity of the method. Study with parabens. Tracks 1-3 (from the bottom side to the upper side): haloperidol; tracks 4-6: haloperidol + methylparaben; tracks 7-9: haloperidol + propylparaben; tracks 10-12: haloperidol + methylparaben + propylparaben. Peak 1(from left to right): haloperidol; peak 2: solvent front. Rf: retarding factor. AU: absorbance unit




Fig. 10. Picture (video store, CAMAG) of plate at selectivity between haloperidol and parabens. Tracks 1-3: haloperidol; tracks 4-6: haloperidol + methylparaben; tracks 7-9: haloperidol + propylparaben; tracks 10-12: haloperidol + methylparaben + propylparaben. Bands of parabens can be observed at the solvent front

After treatment of haloperidol lactate with acid none degradation product was found. However, after treatment with basic, one minor peak was found, which probably correspond to a degradation product, with a resolution of 2.4 between haloperidol and another peak (Fig. 11)




Fig. 11. Selectivity of the method. Study at forced degradation of haloperidol with 0.1 N HCl and 0.1 N NaOH. Tracks 1,2,7,8 (from the bottom side to the upper side): haloperidol; tracks: 3-4: haloperidol + HCl; tracks 5-6: haloperidol + NaOH. Peak 1 (from left to right): haloperidol; peak 2: solvent front. Minor peak at tracks 5-6: degradation products. Rf: retarding factor; AU: absorbance unit

When the drug was exposed to forced degradation with VIS radiation, no degradation product was found.

The degradation products for haloperidol mentioned in literature are acrolein, chlorobenzene, p-fluorobenzaldehyde, p-fluoroacetophenone, p-fluorophenyl propenyl ketone, when haloperidol was irradiated with a sterilising dose of gamma radiation (Lund et al., 1994). Another studies found 4-(4-chlorophenyl)-4-hidroxypiperydine and 4-fluorobenzoic acid, presumed to be hydrolytic products of haloperidol (Jemal et al., 2005; Karipnska et al., 2005) and 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidiny]-1-(4-fluorophenyl)-1-butanone N-oxide; and 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidiny]-1-(4-hydroxyphenyl)-1-butanone; 4-[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-piperidiny]-1-(4-fluorophenyl)-1-butanone (Lund et al., 1994).

Values for the precision study are shown at the Table 3.

Concentration (ng/uL)	Relative standard deviation (RSD), %		
	Instrumental precision <sup>a</sup>	Intraassay precision <sup>b</sup>	Intermediate precision <sup>c</sup>
10	0.81	1.31	1.92
50	0.37	1.74	1.53
100	0.51	0.38	1.11

<sup>a</sup> n= 10; analyzed on the same day  
<sup>b</sup> n= 5; analyzed on the same day (for each concentration)  
<sup>c</sup> n= 9; analyzed on three different days (for each concentration)

Table 3. Precision of the method

Values for the accuracy of the method can be observed at the Table 4.

Added concentration (ng/uL)	Found concentration (ng/uL) <sup>a</sup>	Accuracy, % <sup>b</sup>	
Intraassay (n=9)			
80	78.87 ± 2.98	98.59	3.78
100	101.21 ± 3.78	101.21	3.74
120	119.05 ± 1.75	99.21	1.47
Interassay (n=27)			
80	81.52 ± 3.59	101.90	4.40
100	99.74 ± 4.41	99.74	4.42
120	119.35 ± 5.37	99.46	4.50

<sup>a</sup> Each value is the mean ± standard deviation.;  
<sup>b</sup> (Founded concentration/ added concentration) x 100;  
<sup>c</sup> Relative standard deviation (coefficient of variation).

Table 4. Method accuracy

Stability study of haloperidol lactate injection 5mg /mL was realized at the following conditions: 25 ± 2 °C, because it is the more common temperature founded at hospitals in Chile and is the temperature mentioned by ICH guidelines for stability studies at dosage forms; and refrigeration temperature (8 ± 1 °C) in its original glass ampoules after it was opened, removed a portion of drug, and sealed with Teflon. The samples at room temperature were stored under light exposure and light protection. The study was performed over 15 days.

Samples were taken at appropriate time intervals (0, 3, 5, 7, 10 and 15 days), and analyzed in duplicate by HPTLC to determine haloperidol concentration. For stability study, 100 uL of the haloperidol lactate injection 5 mg/mL was transferred to a 10 mL volumetric flask and diluted with methanol to volume (final concentration of 50 ng/uL).

The percentage of haloperidol remaining after each interval was determined by comparing the concentration at that time with the initial haloperidol concentration, measured before storage (t = 0) at the different conditions. Haloperidol lactate injections, when stored at 25 ± 2 °C under light exposure and light protection, and when stored at refrigeration temperature (8 ± 1 °C) in original glass ampoules opened and after closed with Teflon retained at least 90% of the initial concentration over 15 days (Table 5).

Storage time (days)	Initial concentration remaining (%) (Mean ± SD)		
	23 ± 2 °C		8 ± 1 °C
	Exposed to light		Protected from light
0	100 .00	100.00	100.00
3	94.77 ± 0.6	96.20 ± 2.1	98.99 ± 0.3
5	93.64 ± 1.4	94.79 ± 0.8	98.75 ± 1.2
7	93.26 ± 2.1	93.20 ± 1.8	96.99 ± 1.4
10	91.87 ± 0.3	92.88 ± 2.0	94.75 ± 2.1
15	90.69 ± 1.7	91.71 ± 0.5	92.53 ± 0.8

Table 5. Stability of injectable haloperidol

3.1.3 Method for L-DOPA tablets

For the quantification of L-DOPA in tablets, the method was linear between 100 ng/band to 500 ng/ band (r = 0.999). The intra-assay variation was between 0.26% and 0.65% and the inter-assay was between 0.52% and 2.04%. LOD was 1.12 ng, and LOQ was 3.29 ng. The accuracy ranged from 100.40 % to101.09%, with a coefficient of variation not higher than 1.40%. The method was selective for L-DOPA (Rf = 0.37) and carbidope (Rf = 0.79) (Fig. 12).

Table 6 shown the values for the precision study of the method.

The values found for the accuracy of the method can be observed at Table 7.

At Table 8 can be observed the values found for the determination of L-DOPA in tablets by the proposed HPTLC method and by the USP HPLC method.

Accelerated stability study was performed on commercial tablets of L-DOPA. The temperature used was 40±2°C and the relative humidity was 75±5 (Zone II, OMS). The study was carried out by three months, taking samples to t=0 and one time each month.

Concentration (ng/ µL)	Relative standard deviation (RSD), %		
	Instrumental precision <sup>a</sup>	Intraassay precision <sup>b</sup>	Intermediate precision <sup>c</sup>
100	0.45	0.48	2.04
300	0.68	0.65	0.77
500	0.23	0.26	0.52

<sup>a</sup> n= 10; analyzed on the same day; <sup>b</sup> n= 5; analyzed on the same day (for each concentration)  
<sup>c</sup> n= 9; analyzed on three different days (for each concentration)

Table 6. Precision of the method




Fig. 12. Selectivity of the method. Peak 1 (from left to right): L-DOPA; peak 2: Carbidope (dopa-decarboxilase inhibitor)

Added concentration (ng/ $\mu$ L)	Found concentration (ng/ $\mu$ L) <sup>a</sup>	Accuracy, % <sup>b</sup>	RSD, %
Intraassay (n=9)			
320	322.10 $\pm$ 4.20	100.66	1.30
400	404.22 $\pm$ 3.70	101.06	0.92
480	485.25 $\pm$ 1.20	101.09	0.25
Interassay (n=27)			
320	321.27 $\pm$ 4.50	100.40	1.40
400	402.30 $\pm$ 3.80	100.58	0.94
480	482.83 $\pm$ 2.35	100.60	0.49

<sup>a</sup> Each value is the mean  $\pm$  standard deviation; <sup>b</sup> (Found concentration/ added concentration)  $\times$  100.

Table 7. Method accuracy

Parameter	HPTLC	HPLC
Labelled claim (mg per tablet)	100.00	100.00
Amount found <sup>a</sup> (mg per tablet)	90.99	90.00
RSD (%)	2.40	1.53

$F$  calc.: 11.86;  $F$  theoretical<sup>b</sup>: 13.61

<sup>a</sup> Each result is the mean of nine experiments (three solutions, three determinations of each of them).

<sup>b</sup>  $\alpha$  = 0.05

Table 8. Comparison for determination of L-DOPA in tablets by the proposed method and by HPLC

Tablets were processed as follow (USP, 2007): 20 tablets were weighed and ground into fine powder and an accurately weighed portion equivalent to 30 mg of L-DOPA was diluted to 100 mL with water: methanol (7:3, v/v) . The solution was centrifuged and then, 1 mL of the supernatant was diluted to a 10 mL with the mixture solvent.

Results of the accelerated stability study can be observed at Table 9.

t(months)	Percentage L-DOPA per tablet	Quantity L-DOPA per tablet (mg)
0	100.00	90.99
1	96.65	87.94
2	87.21	79.35
3	85.60	77.89

Table 9. Results for the accelerated stability study of L-DOPA tablets

Therefore, at the second month of accelerated stability study, L-DOPA tablets don’t have a change significant at the percentage of active principle per tablet, but at the third month of the study, the change at the percentage is more than a 5% (ICH, 2003).

4. Conclusion

The proposed HPTLC methods are a new analytical alternative for quantification of the mentioned drugs in these dosage forms. None HPTLC method for quantitative analysis of fluphenazine hydrochloride in injections, haloperidol in injections and L-DOPA in tablets were found in literature before our methods. These methods are simple, fast, precise, sensitive (low LOD and LOQ values), accurate and specifics for the quantification of these drugs in the dosage forms studied. Moreover, HPTLC allows for a large number of samples to be measured simultaneously, very important, especially in quality control. The procedure works without separation steps, only centrifugation, because the excipients are not dissolved by the working solvents. Therefore, the proposed HPTLC methods are very good methods for quantitative analysis of fluphenazine hydrochloride in injection, haloperidol lactate in injections, and L-DOPA in tablets, being appropriate to stability studies. By the other side, the results indicate that haloperidol lactate injection (glass ampoules) could be stored for at least 15 days and use when needed, reducing wastage and unnecessary expenses. This could result in substantial money savings for some institutions.

5. Acknowledgment

The authors would like to thank the Research Council at the University of Concepción (Project DIUC 201.074.034-1.0 and Project DIUC 204.074.034-1.0), and to Pharmacists Miss Loreto Pino, Mr. Mario Nail, Mr. Jonathan Contreras and Mr. Cristobal Reyes.

6. References

Ali, I., & Aboul-Enein, H. (2005). Fast determination of haloperidol in pharmaceutical preparations using HPLC in monolithic silica column. *J.Liq. Chromatogr. Relat. Technol.*, 28, 3169-3179.

Blanco, M; Coello, M., Iturriaga, H., Maspocho, S., & Villegas, N. (2000) Simultaneous spectrophotometric determination of levodopa and benserazide in a pharmaceutical. *Anal. Lett.* , 33 (13), 2701-2718.

Carstensen, J. (1990). *Drug Stability. Principles and Practices*, Marcel Dekker, Inc., New York, USA.



- Chaná, P., Kunstmann, C., Reyes-Parada, M., & Sáez-Briones, P.(2004). Delayed early morning turn „ON“ in response to a single dose of levodopa in advanced Parkinson´s disease: pharmacokinetics should be considered. *J. Neurol. Neurosurg. Psychiatrie*, 75, 1782-1783
- Connors, K; Amidon, G., & Stella, V.(1986). *Chemical Stability of Pharmaceuticals*, John Wiley & Sons, New York, USA.
- Crevoisier, C., Monreal, A., Metzger, B., & Nilsen, T.(2003). Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. *Eur.Neurol.*, 49, 39-44.
- Damiani, P., Moschetti, A., Rovetto, A., Benavente, F., & Olivieri, A.(2005). Design and optimization of a chemometrics-assisted spectrophotometric method for the simultaneous determination of levodopa and carbidopa in pharmaceutical products. *Anal. Chim. Acta*, 543 (1-2), 192-198.
- Das Gupta, V., & Stewart, K.R. (1982). Stability of haloperidol in 5% dextrose injection. *Am.J.Hosp.Pharm.*, 1982, 39(2), 292-294.
- de Diego, M.,Godoy, C.G., & Mennickent, S.(2007). Chemical stability of midazolam injection for high performance liquid chromatography. *J.Sep.Sci.*, 30 (12), 1833-1838.
- de Diego, M., Avello, M., Mennickent, S., Fernández, M., & Fernández., P. (2007). Validated liquid chromatographic method for the quantification of allicin in garlic powder and tablets.. *J.Sep.Sci.*, 30(16),2703-2707.
- de Diego, M.,Godoy, C.G., & Mennickent, S.(2010). Chemical stability of ceftriazone by a validated stability-indicating liquid chromatographic method. *J.Chil.Chem.Soc.*, 55 (3): 335-337.
- de Diego, M., Godoy, R., Godoy, C.G., & Mennickent, S. (2010). "Chemical stability of enalapril maleate drug substance and tablets by a stability-indicating liquid chromatographic method".*Química Nova*. In press, 2010.
- Delgado, J., & Remers, W. (1998). *Wilson and Gisvolds. Textbook of Organic Medicinal and Pharmaceutical Chemistry*, Lippincott-Raven, Philadelphia, USA.
- Fernández, M., Fernández, T., García, B., Gutiérrez, J., & Iraizoz, A. (2001). Accelerated stability of levodopa-carbidopa tablets. *Rev. Cubana Farm.*, 35 (2),1-5.
- Gennaro, A. (2000). *Remington: the Science and Practice of Pharmacy*, Lippincott Williams /Wilkins, Philadelphia, USA.
- Hardman, J., & Limbird, L. (2006).*Las Bases Farmacológicas de la Terapéutica*, Mc Graw-Hill, Mexico, Mexico.
- Jemal, M., Ivanshiv, E., Both, D., Koski, R., & Cohen, A. (2005). Picogram level determination of fluphenazine in human plasma by automated gas chromatography/mass selective detection. *Biomed. Environ. Mass Spectrom.*, 14, 699-704.
- Karimi, M., Carl, J.L., Loftin, S., & Perlmutter, J.S. (2006). Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O methyldopa, dopamine, carbidope and 3,4-dihydroxyphenyl acetic acid. *J.Chromatogr. B.*, 19 (1-2), 120-123.
- Karpinska, J., Smyk, J., & Wolyniec, E. (2005). A spectroscopic study on applicability on spectral analysis for simultaneous quantificatin of l-dopa, benserazide and ascorbic acid in batch and flow systems. *Spectrochim. Acta A Mol Biomol. Spectrosc.*, 62 (1-3), 213-220.
- Kircherr, H., & Kühn-Velten, W. (2006). Quantitative determination of forthy-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi level, single sampling approach. *J.Chromatogr.B*, 843,100-113.



- Lea, A.R., Haley, D.M., & Daguid, P.R. (1982). Analysis of haloperidol tablets by high-performance liquid chromatography –an inter-laboratory study. *J.Chromatogr.*, 250, 35-42.
- Lund, W. (1994) *The Pharmaceutical Codex*, The Pharmaceutical Press, London, UK.
- Maia, M.S., Yamashita, M., & Angnes, L. (2005). Voltammetric studies and determination of levodopa and carbidopa in pharmaceutical products. *Electroanalysis*, 18 (7), 656-661.
- Madrakian, T., Afkhami, M., Borazjani, M., & Bahram, M. (2004). Simultaneous derivative spectrophotometric determination of levodopa and carbidopa in pharmaceutical preparations. *Bull. Korean Chem. Soc.*, 25 (12), 1764-1767.
- Madrakian, T., Afkhami, A., Khalafi, L., & Mohammadnejad, M. (2006). Spectrophotometric determination of catecholamines based on their oxidation reaction followed by coupling with 4 -aminobenzoic acid. *J.Braz. Chem. Soc.*, 17 (7), 1-20.
- Marcolino-Junior, L.H., Teixeira, M.F., Pereira, A.V., & Fatibello-Filho (2001). Flow injection determination of levodopa in tablets using a solid-phase reactor containing lead (IV) dioxide immobilized. *J.Pharm.Biomed.Anal.*, 25 (3-4), 393-398.
- Maslanka, A., & Krzek, J. (2005). Densitometric high performance thin-layer chromatography identification and quantitative analysis of psychotropic drugs. *JAOAC Inter.*, 88, 70-79.
- Mc Evoy, G. (2006). *AHFS Drug Information*, American Society of Health- System Pharmacists, Bethesda, USA.
- Moffat, A., Osselton, M.D., & Widdop, B. (2004). *Clarke's Analysis of Drugs and Poisons*, Pharmaceutical Press, London, UK.
- Mennickent, S., Vega, M., & Godoy, C.G. (2003). Development and validation of a method using instrumental planar chromatography for quantitative analysis of carbamazepine in saliva. *J.Chil.Chem.Soc.*, 48, (3), 71-73.
- Mennickent, S., Sobarzo, A., Vega, M., Godoy, C.G., & de Diego, M. (2007). Quantitative determination of clozapine in serum by instrumental planar chromatography. *J.Sep.Sci.*, 30, 2167 -2172.
- Mennickent, S., Vega, M., Godoy, C.G., & León, M.D. (2007). Relación entre niveles de carbamazepina en saliva y plasma: un estudio piloto. *Rev.Méd.Chile*, 135: 335-340.
- Mennickent, S., Pino, L., Vega, M., Godoy, C.G., & de Diego, M. (2007). Quantitative determination of haloperidol in tablets by high performance thin-layer chromatography. *J. Sep. Sci.*, 30, 772-777.
- Mennickent, S., Pino, L., Vega, M., & de Diego, M. (2007). Chemical stability of haloperidol injection by high performance thin - layer chromatography. *J.Sep.Sci.*, 31, 201-206.
- Mennickent, S., Nail, M., Vega, M., & de Diego, M. (2007). Quantitative determination of L-DOPA in tablets by high performance thin-layer chromatography. *J.Sep.Sci.*, 30, 1893-1898.
- Mennickent, S., Fierro, R., Vega, M., de Diego, M., & Godoy, C.G. (2009) Instrumental planar chromatographic method for determination of carbamazepine in human serum. *J.Sep.Sci.*, 32, 1454 -1458.
- Mennickent, S., Sobarzo, A., Vega, M., de Diego, M., Godoy, C.G., Rioseco, P., & Saavedra, L. (2010). Determination of clozapine in serum of patients with schizophrenia as a measurement of medication compliance. *International Journal of Psychiatry in Clinical Practice*, 14, 41-46.
- Mennickent, S., Fierro, R., Vega, M., de Diego, M., & Godoy, C.G. (2010). Quantitative determination of fluoxetine in human serum by high performance thin layer chromatography. *J.Sep.Sci.*, 33, 2206 -2210.

- Mennickent, S., Contreras, J., Reyes, C., Vega, M., & de Diego, M. (2010). Validated instrumental planar chromatographic method for quantification of fluphenazine hydrochloride in injections. *J. Planar Chromatogr.*, 23, 1-13.
- Nagaraja, P., Vasantha, R.A., & Sunitha, K.R. (2001). A new sensitive and selective spectrophotometric method for determination of catechol derivatives and its pharmaceutical preparations. *J. Pharm. Biomed. Anal.*, 25 (3-4), 417-424.
- Nagaralli, B.S., Seetharamappa, J., Melwanki, M.B., Ramesh, K.C., & Keshavayya, J. (2002). Spectrophotometric investigations of the assay physiologically active catecholamines in pharmaceutical formulations. *J. AOAC Inter.*, 85 (6), 1288-1292.
- Nour El-Dien, F.A., Zayed, M.A., Mohamed, G., & El-Nahas, R. (2005). Two spectrophotometric assays for dopamine derivatives in pharmaceutical products and in biological samples of schizophrenic patients using copper tetramine complex and tri-iodide reagent. *J. Biomed. Biotechnol.*, 205 (1), 9.
- Nyholm, D., Lennernans, H., Gomes-Trolin, C., & Aquilonius, S-M. (2002). Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. *Clin. Neuropharmacol.*, 25 (2), 89-96.
- Pistonesi, M., Centurión, M.E., Fernández, B., Damiani, P., & Olivieri, A. (2004). Simultaneous determination of levodopa and benserazide by stopped-flow injection analysis and three-way multivariate calibration of kinetic-spectrophotometric data. *J. Pharm. Biomed. Anal.*, 36, 541-547.
- Sagar, K.A., & Smyth, M.R. (2000). Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. *Analyst*, 125, 439-445.
- Saxer, C., Nilna, M., Nakashima, A., Nagae, Y., & Masude, N. (2004). Simultaneous determination of levodopa and 3-O-methyldopa in human plasma by liquid chromatography with electrochemical detection. *J. Chromatogr. B.*, 802 (2), 299-305.
- Sweetman, S. (2003). Martindale. *Guía Completa de Consulta Farmacoterapéutica*, Pharma Editores S.L, Barcelona, Spain.
- Talebpour, Z., Haghgoo, S., & Shamsipur, M. (2005). HNMR spectroscopy analysis for simultaneous determination of levodopa, carbidopa and methyldopa in human serum and pharmaceutical formulations. *Anal. Chim. Acta*, 506 (1), 97-104.
- The Sixth ICH International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2003). Osaka, Japan.
- The United States Pharmacopeia (USP 30) (2007). United States Pharmacopeial Convention, Inc., Rockville, USA.
- Trabelsi, H., Bouzouita, K., & Safta, F. (2002). Determination and degradation study of haloperidol by high performance liquid chromatography. *J. Pharm. Biomed. Anal.*, 29 (4), 649-657.
- Wang, J., & Fang, Y. (2006). Determination, purity assessment and chiral separation of levodopa methyl ester in bulk and formulation pharmaceuticals. *Biomed. Chromatogr.*, 20 (9), 904-910.
- Watson, D. (2005). *Pharmaceutical Analysis*, Elsevier, Edinburgh, UK.
- Yoshioka, S., & Stella, V. (2000). *Stability of Drugs and Dosage Forms*, Kluwer Academic Plenum Publishers, New York, USA.
- Zhang, L., Chen, G., Hu, Q., & Fang, Y. (2001). Separation and determination of levodopa and carbidopa in composite tablets by capillary zone electrophoresis with amperometric detection. *Anal. Chim. Acta*, 43(2), 287-292.



## **Quality Control of Herbal Medicines and Related Areas**

Edited by Prof. Yukihiro Shoyama

ISBN 978-953-307-682-9

Hard cover, 282 pages

**Publisher** InTech

**Published online** 07, July, 2011

**Published in print edition** July, 2011

The authors of this thematic issue provide a comprehensive summary of most recent knowledge and references on quality control in wide fields. Quality control is essential for natural products like natural medicine and related food products. In this issue fifteen chapters have been included, discussing in detail various aspects of quality control. It will certainly prove useful not only for phytochemical researchers, but also many scientists working in numerous fields. Much effort has been invested by the contributors to share current information. Without their efforts and input 'Quality Control of Herbal Medicine and Related Areas' could not exist.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Sigrid Mennickent, Marta de Diego, Mario Vega and Carmen Gloria Godoy (2011). Quantitative Determination of Drugs in Dosage Forms as a Tool of Quality Control Studies, *Quality Control of Herbal Medicines and Related Areas*, Prof. Yukihiro Shoyama (Ed.), ISBN: 978-953-307-682-9, InTech, Available from: <http://www.intechopen.com/books/quality-control-of-herbal-medicines-and-related-areas/quantitative-determination-of-drugs-in-dosage-forms-as-a-tool-of-quality-control-studies>

**INTECH**  
open science | open minds

### **InTech Europe**

University Campus STeP Ri  
Slavka Krautzeka 83/A  
51000 Rijeka, Croatia  
Phone: +385 (51) 770 447  
Fax: +385 (51) 686 166  
[www.intechopen.com](http://www.intechopen.com)

### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai  
No.65, Yan An Road (West), Shanghai, 200040, China  
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元  
Phone: +86-21-62489820  
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen